Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Fortrea Holdings Inc.
Fortrea runs clinical trials and manages patient access to medicines for drug and device makers.
Fortrea is a hired hand for the drug business. When a biotech or medical device company has a promising molecule or gadget, it still needs to prove the thing actually works and is safe in people. That means designing a study, finding hospitals and doctors to run it, recruiting the right patients, collecting the data, and keeping regulators happy. Fortrea does all of that for a fee, so its customers can focus on science instead of logistics.
The company was spun out of Labcorp in mid-2023, taking the contract research piece of that business and leaving the lab-testing side behind. It sells two broad things. The bigger one is clinical trial management, the day-to-day running of studies from early-stage safety tests through large late-stage trials. The smaller one is patient access, which helps patients get and stay on medicines — think nursing support, reimbursement help, and getting drugs to people who need them outside a hospital. The awkward truth about this business is that it is a people business. Fortrea employs thousands of clinicians, project managers, and data specialists, and it competes against much larger rivals like IQVIA, ICON, and Syneos Health (the last now private). Size matters because big drugmakers want one partner who can run trials across many countries, and scale lets rivals spread fixed costs. Fortrea is the smaller challenger, still building out its systems after the split, and it has struggled with profitability and losing money in recent years.
Its customers are the biopharma, device, and diagnostics companies that pay per study, often on multi-year contracts. Winning a contract means years of revenue, but the work is lumpy and margins can be thin when studies are slow to start. The real question for investors is whether Fortrea can fix its cost base, keep winning bids, and turn its order book into steady cash — or whether the bigger players simply squeeze it out.
Saved answer · last researched 15 Nov 2026